Open main menu

Template:Androgen/anabolic steroid dosages for breast cancer

Androgen/anabolic steroid dosages for breast cancer

Route/form Androgen Dosage Ref(s)
Oral Methyltestosterone 30–200 mg/day [1][2][3]
Fluoxymesterone 10–40 mg 3x/day [1][4]
Calusterone 40 mg 4x/day [1]
Normethandrone 40 mg/day [2]
IM injection Testosterone propionate 50–100 mg 3x/week [1][2][5]
Testosterone enanthate 200–400 mg 1x/2–4 weeks [6][7]
Testosterone cypionate 200–400 mg 1x/2–4 weeks [7]
Methandriol (aq. susp.) 100 mg 3x/week [5]
Androstanolone (aq. susp.) 300 mg 3x/week [2][5][8]
Drostanolone propionate 100 mg 3x/week [1][2]
Nandrolone decanoate 50–100 mg 1x/1–3 weeks [9][10][11]
Nandrolone phenylpropionate 50–100 mg/week [12]
Notes: Dosages are not necessarily equivalent.
Template documentation

See also

References

  1. ^ a b c d e Aurel Lupulescu (24 October 1990). "Hormones and Hormonotherapy". Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 33–90. ISBN 978-0-8493-5973-6.
  2. ^ a b c d e Dao, Thomas L. (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli; David G. Johns (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8.
  3. ^ https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/083976s031lbl.pdf
  4. ^ Michael Clinton Perry (2008). The Chemotherapy Source Book. Lippincott Williams & Wilkins. pp. 369–. ISBN 978-0-7817-7328-7.
  5. ^ a b c Council on Drugs (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients". JAMA. 172 (12): 1271–83. doi:10.1001/jama.1960.03020120049010.
  6. ^ https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009165s031lbl.pdf
  7. ^ a b American Medical Association. Division of Drugs; American Society for Clinical Pharmacology and Therapeutics (1983). AMA drug evaluations. American Medical Association. ISBN 978-0-89970-160-8. TESTOSTERONE CYPIONATE [Andro-Cyp, Depo-Testosterone, T-Ionate-P.A.] TESTOSTERONE ENANTHATE [Andryl, Delatestryl] These long-acting, potent esters of testosterone can maintain the testosterone level within the normal range in males for two to four weeks. [...] For metastatic breast carcinoma in women, 200 to 400 mg every two or more weeks.
  8. ^ Segaloff, Albert; Horwitt, Benjamin N.; Cakabasi, Ralph A.; Murison, Path J.; Osser, Joskph V. Scht. (1955). "Hormonal therapy in cancer of the breast.VIII. The effect of dihydrotestosterone (Androstanolone) on clinical course and hormonal excretion". Cancer. 8 (1): 82–86. doi:10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R. ISSN 0008-543X.
  9. ^ https://web.archive.org/web/20190309024812/https://gp2u.com.au/static/pdf/D/DECA-DURABOLIN-PI.pdf
  10. ^ https://web.archive.org/web/20180128030754/http://medsafe.govt.nz/profs/Datasheet/d/Decadurabolininj.pdf
  11. ^ Ronald I. Shorr (11 April 2007). Drugs for the Geriatric Patient E-Book. Elsevier Health Sciences. pp. 844–. ISBN 978-1-4377-1035-9.
  12. ^ W. Llewellyn McKone (11 November 2013). Osteopathic Athletic Health Care: Principles and practice. Springer. pp. 125–. ISBN 978-1-4899-3067-5.